Actively Recruiting
Phase 1 Study of FluBHPVE6E7 Immunotherapy for Adults with HPV16-Associated Oropharyngeal Squamous Cell Carcinoma
Led by BlueSky Immunotherapies GmbH · Updated on 2024-09-19
12
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an immunotherapy called FluBHPVE6E7 in patients with oropharyngeal squamous cell carcinoma OPSCC linked to the HPV16 virus. This cancer type is increasingly common in younger people without traditional risk factors like smoking or alcohol. The study focuses on patients with HPV16-positive OPSCC who have locally advanced disease, aiming to understand the safety and immune response to this new treatment. The study uses FluBHPVE6E7, a biological agent that delivers HPV-16 oncogenes E6 and E7. The first dose is given directly into the tumor, followed by injections into the muscle at scheduled intervals. This is a phase 1 trial led by BlueSky Immunotherapies GmbH, focusing on safety and immune effects over several weeks, with long-term follow-up planned to assess disease-free and overall survival. Participants will undergo various assessments including monitoring for adverse events, immune cell infiltration in the tumor, virus presence in saliva and secretions, and blood tests over 24 weeks and beyond. The study tracks safety closely for 7 days initially and up to 60 months for survival outcomes. Participants will be followed regularly to evaluate immune responses and disease status during and after treatment.
CONDITIONS
Brief Title
Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Research Team
M
Medical University of Vienna
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here